AMEH RSI Chart
Last 7 days
4.4%
Last 30 days
-8.1%
Last 90 days
4.9%
Trailing 12 Months
19.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 1.5B | 0 | 0 | 0 |
2023 | 1.2B | 1.3B | 1.3B | 1.4B |
2022 | 861.1M | 955.2M | 1.0B | 1.1B |
2021 | 698.1M | 708.6M | 755.6M | 773.9M |
2020 | 630.0M | 695.2M | 705.7M | 717.4M |
2019 | 491.7M | 499.1M | 488.5M | 560.6M |
2018 | 394.9M | 476.0M | 545.6M | 519.9M |
2017 | 128.0M | 157.2M | 239.7M | 356.4M |
2016 | 44.0M | 46.2M | 49.5M | 54.5M |
2015 | 33.0M | 39.1M | 38.8M | 41.8M |
2014 | 10.8M | 12.1M | 20.9M | 25.7M |
2013 | 6.6M | 7.1M | 9.3M | 10.3M |
2012 | 5.1M | 5.7M | 6.3M | 6.8M |
2011 | 3.9M | 4.2M | 4.5M | 4.8M |
2010 | 0 | 0 | 0 | 0 |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 23, 2024 | kumar dinesh m. | acquired | - | - | 150,395 | see remarks |
Dec 15, 2023 | marsh linda | acquired | - | - | 3,650 | - |
Dec 15, 2023 | mazdyasni matthew | acquired | - | - | 4,750 | - |
Dec 15, 2023 | vong john | acquired | - | - | 14,352 | chief accounting officer |
Dec 15, 2023 | dai, weili | acquired | - | - | 3,650 | - |
Dec 15, 2023 | chiang john | acquired | - | - | 4,750 | - |
Dec 15, 2023 | schmidt david | acquired | - | - | 5,750 | - |
Dec 15, 2023 | lam thomas s. | acquired | - | - | 90,000 | president and co-ceo |
Dec 15, 2023 | sim kenneth t. | acquired | - | - | 90,000 | executive chairman |
Dec 15, 2023 | kitayama mitchell w | acquired | - | - | 6,750 | - |
Which funds bought or sold AMEH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | PNC Financial Services Group, Inc. | reduced | -5.91 | 2,480 | 80,956 | -% |
May 10, 2024 | DIMENSIONAL FUND ADVISORS LP | added | 7.71 | 5,319,440 | 34,757,100 | 0.01% |
May 10, 2024 | CREDIT SUISSE AG/ | added | 6.05 | 354,543 | 2,534,350 | -% |
May 10, 2024 | CITIGROUP INC | added | 150 | 1,675,010 | 2,631,510 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 12.91 | 126,045 | 655,925 | -% |
May 10, 2024 | BlackRock Inc. | added | 0.53 | 25,414,700 | 274,291,000 | 0.01% |
May 10, 2024 | VANGUARD GROUP INC | added | 0.2 | 19,066,000 | 212,478,000 | -% |
May 10, 2024 | Covestor Ltd | added | 11,620 | 25,000 | 25,000 | 0.02% |
May 10, 2024 | Campbell & CO Investment Adviser LLC | reduced | -73.8 | -760,216 | 306,401 | 0.03% |
May 10, 2024 | JPMORGAN CHASE & CO | reduced | -24.5 | -595,523 | 2,862,580 | -% |
Unveiling Apollo Medical Holdings Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Apollo Medical Holdings Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 466.7B | 379.5B | 30.38 | 1.23 | ||||
CI | 99.7B | 206.0B | 25.87 | 0.48 | ||||
HCA | 84.3B | 66.7B | 15.41 | 1.26 | ||||
CVS | 69.9B | 360.9B | 9.54 | 0.19 | ||||
CNC | 41.4B | 155.5B | 15.15 | 0.27 | ||||
DVA | 12.1B | 12.3B | 14.83 | 0.98 | ||||
UHS | 11.9B | 14.7B | 14.57 | 0.81 | ||||
MID-CAP | ||||||||
CHE | 8.7B | 2.3B | 30.63 | 3.79 | ||||
ACHC | 6.5B | 3.0B | -578.78 | 2.19 | ||||
AMN | 2.3B | 3.5B | 16.07 | 0.66 | ||||
AMEH | 2.2B | 1.5B | 34.91 | 1.5 | ||||
SMALL-CAP | ||||||||
ADUS | 1.8B | 1.1B | 27.24 | 1.64 | ||||
BKD | 1.4B | 3.0B | -7.95 | 0.45 | ||||
BEAT | 52.9M | - | -3.5 | - | ||||
AMS | 19.9M | 21.3M | 37.29 | 0.93 |
Apollo Medical Holdings Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Revenue | 14.5% | 404 | 353 | 348 | 348 | 337 | 294 | 317 | 270 | 263 | 195 | 227 | 176 | 176 | 177 | 180 | 165 | 195 | 165 | 179 | 156 | 130 |
Costs and Expenses | 4.9% | 374 | 357 | 309 | 321 | 315 | 282 | 267 | 254 | 237 | 193 | 174 | 155 | 154 | 137 | 143 | 152 | 189 | 161 | 168 | 146 | 115 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 168 | 146 | 115 |
S&GA Expenses | -100.0% | - | 38.00 | 29.00 | 24.00 | 21.00 | 24.00 | 21.00 | 20.00 | 12.00 | 17.00 | 22.00 | 14.00 | 9.00 | 9.00 | 16.00 | 12.00 | - | 12.00 | 11.00 | 8.00 | 12.00 |
EBITDA Margin | 2.9% | 0.09* | 0.09* | 0.10* | 0.10* | 0.09* | 0.10* | 0.07* | 0.03* | 0.11* | 0.13* | 0.20* | 0.27* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 39.9% | 8.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 1.00 | 2.00 | 3.00 | - | 3.00 | 3.00 | 1.00 | 0.00 |
Income Taxes | 601.9% | 7.00 | 1.00 | 10.00 | 14.00 | 7.00 | 11.00 | 17.00 | 5.00 | 7.00 | -4.28 | -0.28 | 28.00 | 8.00 | 13.00 | 11.00 | 32.00 | - | 2.00 | 2.00 | 4.00 | 4.00 |
Earnings Before Taxes | 2499.2% | 24.00 | 1.00 | 38.00 | 31.00 | 19.00 | 10.00 | 41.00 | 17.00 | 18.00 | -22.43 | -5.50 | 84.00 | 21.00 | 24.00 | 36.00 | 113 | 6.00 | 5.00 | 0.00 | 14.00 | 15.00 |
EBT Margin | 0.3% | 0.06* | 0.06* | 0.07* | 0.08* | 0.07* | 0.08* | 0.05* | 0.01* | 0.09* | 0.10* | 0.16* | 0.23* | - | - | - | - | - | - | - | - | - |
Net Income | 20.1% | 15.00 | 12.00 | 22.00 | 13.00 | 13.00 | -3.73 | 23.00 | 12.00 | 14.00 | 12.00 | 34.00 | 10.00 | 12.00 | 10.00 | 17.00 | 7.00 | 6.00 | 4.00 | 7.00 | 4.00 | 4.00 |
Net Income Margin | -1.9% | 0.04* | 0.04* | 0.03* | 0.04* | 0.04* | 0.04* | 0.06* | 0.08* | 0.08* | 0.09* | 0.09* | 0.07* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -54.2% | 6.00 | 12.00 | 11.00 | 14.00 | 2.00 | 84.00 | -39.08 | 8.00 | 7.00 | -14.99 | 42.00 | 14.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 31.4% | 1,226 | 933 | 1,073 | 1,027 | 999 | 966 | 955 | 967 | 923 | 867 | 871 | 896 | 843 | 817 | 814 | 833 | 724 | 729 | 750 | 568 | 521 |
Current Assets | 16.8% | 539 | 462 | 476 | 465 | 455 | 428 | 446 | 468 | 445 | 404 | 427 | 472 | 370 | 339 | 367 | 381 | 318 | 329 | 321 | 168 | 177 |
Cash Equivalents | 14.2% | 335 | 294 | 274 | 294 | 275 | 288 | 184 | 234 | 238 | 233 | 205 | 177 | 206 | 194 | 166 | 152 | 81.00 | 104 | 230 | 53.00 | 93.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00 | 12.00 | 12.00 |
Goodwill | 47.1% | 410 | 279 | 276 | 274 | 269 | 269 | 251 | 247 | 246 | 246 | 237 | 232 | 232 | 232 | 239 | 239 | 239 | 239 | 237 | 209 | 186 |
Liabilities | 48.1% | 774 | 523 | 458 | 444 | 434 | 408 | 410 | 447 | 397 | 357 | 346 | 356 | 382 | 372 | 386 | 414 | 369 | 368 | 382 | 163 | 126 |
Current Liabilities | 62.5% | 355 | 219 | 203 | 186 | 173 | 149 | 156 | 185 | 156 | 115 | 115 | 126 | 123 | 115 | 131 | 153 | 107 | 105 | 105 | 78.00 | 88.00 |
Long Term Debt | 42.3% | 368 | 259 | 206 | 205 | 205 | 203 | 199 | 199 | 183 | 183 | 183 | 183 | 227 | 230 | 226 | 230 | 230 | 232 | 234 | - | - |
LT Debt, Current | 6.4% | 21.00 | 20.00 | 3.00 | 3.00 | 1.00 | 1.00 | 3.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 | 12.00 | 11.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | - | - |
LT Debt, Non Current | -100.0% | - | 259 | 206 | 205 | 205 | 203 | 199 | 199 | 183 | 183 | 183 | 183 | 227 | 230 | 226 | 230 | 230 | 232 | 234 | - | - |
Shareholder's Equity | 7.1% | 658 | 614 | 594 | 570 | 551 | 543 | 504 | 480 | 473 | 454 | 435 | 399 | 347 | 329 | 229 | 208 | 198 | 192 | 192 | 186 | 182 |
Retained Earnings | 6.1% | 258 | 243 | 231 | 209 | 196 | 182 | 186 | 163 | 151 | 137 | 125 | 90.00 | 80.00 | 68.00 | 60.00 | 43.00 | 36.00 | 32.00 | 25.00 | 21.00 | 18.00 |
Additional Paid-In Capital | 6.6% | 395 | 371 | 363 | 357 | 353 | 360 | 315 | 311 | 316 | 311 | 306 | 306 | 266 | 261 | 169 | 164 | 161 | 160 | 166 | 164 | 163 |
Shares Outstanding | 1.3% | 47.00 | 47.00 | 47.00 | 47.00 | 46.00 | 47.00 | 45.00 | 45.00 | 45.00 | 45.00 | 44.00 | 44.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | 84.3% | 4.00 | 2.00 | 4.00 | 4.00 | 3.00 | 2.00 | 3.00 | 6.00 | 6.00 | 6.00 | 4.00 | 3.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Float | - | - | - | - | 1,300 | - | - | - | 1,500 | - | - | - | 2,400 | - | - | - | 504 | - | - | - | 480 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -69.0% | 5,977 | 19,300 | 15,405 | 25,802 | 7,720 | 84,939 | -35,870 | 9,021 | 24,038 | -12,190 | 51,239 | 21,334 | 9,952 | -2,601 | 36,189 | 21,868 | -9,293 | 3,588 | 32,102 | -18,050 | -3,967 |
Share Based Compensation | -33.7% | 5,748 | 8,676 | 5,706 | 4,213 | 3,445 | 5,624 | 3,502 | 3,920 | 3,055 | 2,423 | 1,420 | 1,556 | 1,346 | 825 | 600 | 900 | 1,058 | 541 | 330 | 331 | 345 |
Cashflow From Investing | -521.7% | -71,039 | -11,427 | -34,875 | -5,186 | -14,035 | 13,201 | -8,086 | 7,497 | -19,725 | 39,084 | -12,742 | -10,494 | 692 | 29,096 | -753 | 68,093 | -943 | -120,267 | -10,117 | -50,135 | -112 |
Cashflow From Financing | 786.8% | 106,351 | 11,993 | -510 | -963 | -7,099 | 5,871 | -6,251 | -20,237 | 532 | 1,435 | -11,016 | -39,429 | 1,262 | 647 | -21,795 | -18,487 | -12,061 | -10,376 | 152,076 | 31,441 | -9,810 |
Dividend Payments | -100.0% | - | 59,808 | 1,424 | 722 | 120 | 1,354 | 120 | 11,378 | 1,178 | - | 9,979 | 21,106 | 4.00 | 1,186 | 19,946 | - | 9,934 | 1,047 | 49,728 | 942 | 10,000 |
Buy Backs | - | - | - | 150 | 9,539 | - | -423 | 168 | 9,300 | 230 | - | 2,758 | 2,639 | 342 | -1,022 | 771 | 362 | 426 | 7,530 | - | - | 40.00 |
CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue | |||
Total revenue | $ 1,386,661 | $ 1,144,163 | $ 773,915 |
Operating expenses | |||
Cost of services, excluding depreciation and amortization | 1,171,703 | 944,685 | 596,142 |
General and administrative expenses | 112,597 | 77,670 | 62,077 |
Depreciation and amortization | 17,748 | 17,543 | 17,517 |
Total expenses | 1,302,048 | 1,039,898 | 675,736 |
Income from operations | 84,613 | 104,265 | 98,179 |
Other income (expense) | |||
Income (loss) from equity method investments | 5,579 | 5,622 | (4,306) |
Gain on sale of equity method investment | 0 | 0 | 2,193 |
Interest expense | (16,102) | (7,920) | (5,394) |
Interest income | 14,208 | 1,976 | 1,571 |
Unrealized loss on investments | (4,581) | (21,271) | (10,745) |
Other income (loss) | 6,121 | 3,944 | (3,750) |
Total other income (expense), net | 5,225 | (17,649) | (20,431) |
Income before provision for income taxes | 89,838 | 86,616 | 77,748 |
Provision for income taxes | 31,989 | 40,875 | 31,693 |
Net income | 57,849 | 45,741 | 46,055 |
Net (loss) income attributable to noncontrolling interests | (2,868) | 570 | (22,868) |
Net income attributable to Astrana Health, Inc. | $ 60,717 | $ 45,171 | $ 68,923 |
Earnings per share – basic (in dollars per share) | $ 1.30 | $ 1.00 | $ 1.57 |
Earnings per share – diluted (in dollars per share) | $ 1.29 | $ 0.99 | $ 1.52 |
Capitation, net | |||
Revenue | |||
Total revenue | $ 1,215,614 | $ 930,131 | $ 593,224 |
Risk pool settlements and incentives | |||
Revenue | |||
Total revenue | 63,468 | 117,254 | 111,627 |
Management fee income | |||
Revenue | |||
Total revenue | 38,677 | 41,094 | 35,959 |
Fee-for-service, net | |||
Revenue | |||
Total revenue | 59,658 | 49,517 | 26,564 |
Other revenue | |||
Revenue | |||
Total revenue | $ 9,244 | $ 6,167 | $ 6,541 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | ||
---|---|---|---|---|
Current assets | ||||
Cash and cash equivalents | $ 293,807 | $ 288,027 | ||
Investment in marketable securities | 2,498 | 5,567 | ||
Income taxes receivable | 10,657 | 0 | ||
Other receivables | 1,335 | 1,834 | ||
Prepaid expenses and other current assets | 17,450 | 14,798 | ||
Total current assets | 461,507 | 428,125 | ||
Non-current assets | ||||
Land, property and equipment, net | 7,171 | 108,536 | ||
Intangible assets, net | 71,648 | 76,861 | ||
Goodwill | 278,831 | 269,053 | ||
Income taxes receivable | 15,943 | 15,943 | ||
Loans receivable, non-current | 26,473 | 0 | ||
Investments in other entities – equity method | 25,774 | 40,299 | ||
Investments in privately held entities | 6,396 | 2,396 | ||
Restricted cash | 345 | 0 | ||
Operating lease right-of-use assets | 37,396 | 20,444 | ||
Other assets | 1,877 | 4,556 | ||
Total non-current assets | 471,854 | 538,088 | ||
Total assets | [1] | 933,361 | 966,213 | |
Current liabilities | ||||
Accounts payable and accrued expenses | 59,949 | 49,562 | ||
Fiduciary accounts payable | 7,737 | 8,065 | ||
Medical liabilities | 106,657 | 81,255 | ||
Income taxes payable | 0 | 4,279 | ||
Dividend payable | 638 | 664 | ||
Finance lease liabilities | 646 | 594 | ||
Operating lease liabilities | 4,607 | 3,572 | ||
Current portion of long-term debt | 19,500 | 619 | ||
Other liabilities | 18,940 | 0 | ||
Total current liabilities | 218,674 | 148,610 | ||
Non-current liabilities | ||||
Deferred tax liability | 4,072 | 14,217 | ||
Finance lease liabilities, net of current portion | 1,033 | 1,275 | ||
Operating lease liabilities, net of current portion | 36,289 | 19,915 | ||
Long-term debt, net of current portion and deferred financing costs | 258,939 | 203,389 | ||
Other long-term liabilities | 3,586 | 20,260 | ||
Total non-current liabilities | 303,919 | 259,056 | ||
Total liabilities | [1] | 522,593 | 407,666 | |
Commitments and contingencies (Note 14) | ||||
Mezzanine (deficit) equity | ||||
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (“APC”) | (205,883) | 14,237 | ||
Stockholders’ equity | ||||
Common stock, par value $0.001; 100,000,000 shares authorized, 46,843,743 and 46,575,699 shares outstanding, excluding 10,584,340 and 10,299,259 treasury shares, at December 31, 2023 and 2022, respectively | 47 | 47 | ||
Additional paid-in capital | 371,037 | 360,097 | ||
Retained earnings | 243,134 | 182,417 | ||
Stockholders' equity attributable to parent | 614,218 | 542,561 | ||
Non-controlling interest | 2,433 | 1,749 | ||
Total stockholders’ equity | 616,651 | 544,310 | ||
Total liabilities, mezzanine equity (deficit), and stockholders’ equity | 933,361 | 966,213 | ||
Series A Preferred Stock | ||||
Stockholders’ equity | ||||
Preferred stock | 0 | 0 | ||
Series B Preferred Stock | ||||
Stockholders’ equity | ||||
Preferred stock | 0 | 0 | ||
Nonrelated Party | ||||
Current assets | ||||
Receivables, net | 76,780 | 49,631 | ||
Loans receivable, net | 0 | 996 | ||
Related Party | ||||
Current assets | ||||
Receivables, net | 58,980 | 65,147 | ||
Loans receivable, net | $ 0 | $ 2,125 | ||
|